These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3064426)

  • 1. [The status of research to develop new vaccines against infection caused by the respiratory syncytial virus].
    Pervikov IuV; Litvinov SK
    Vopr Virusol; 1988; 33(5):523-9. PubMed ID: 3064426
    [No Abstract]   [Full Text] [Related]  

  • 2. Approaches to immunization against respiratory syncytial virus.
    Wertz GW; Sullender WM
    Biotechnology; 1992; 20():151-76. PubMed ID: 1600380
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vaccination against respiratory syncytial infection].
    Leshchinskaia NP
    Vopr Virusol; 1986; 31(5):517-27. PubMed ID: 3541385
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunological markers of an attenuated bovine respiratory syncytial (BRS) virus vaccine.
    Zygraich N; Wellemans G
    Zentralbl Veterinarmed B; 1981; 28(5):355-62. PubMed ID: 6798786
    [No Abstract]   [Full Text] [Related]  

  • 5. [Respiratory syncytial virus and immune response: from the diagnosis of infection to prospects of vaccination].
    Pothier P
    Pediatrie; 1991; 46(8-9 Suppl):1-4. PubMed ID: 1665219
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent developments with live-attenuated recombinant paramyxovirus vaccines.
    Le Bayon JC; Lina B; Rosa-Calatrava M; Boivin G
    Rev Med Virol; 2013 Jan; 23(1):15-34. PubMed ID: 22570186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine respiratory syncytial virus-specific immune responses in cattle following immunization with modified-live and inactivated vaccines. Analysis of the specificity and activity of serum antibodies.
    Ellis JA; Russell H; Cavender J; Haven TR
    Vet Immunol Immunopathol; 1992 Oct; 34(1-2):35-45. PubMed ID: 1441228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
    Murphy BR; Walsh EE
    J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live viral vaccines for respiratory and enteric tract diseases.
    Chanock RM; Murphy BR; Collins PL; Coelingh KV; Olmsted RA; Snyder MH; Spriggs MK; Prince GA; Moss B; Flores J
    Vaccine; 1988 Apr; 6(2):129-33. PubMed ID: 2838984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective and disease-enhancing immune responses to respiratory syncytial virus.
    Anderson LJ; Heilman CA
    J Infect Dis; 1995 Jan; 171(1):1-7. PubMed ID: 7798649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospects of respiratory syncytial virus vaccines].
    Tarro G
    Ann Sclavo; 1980; 22(1):40-1. PubMed ID: 7247482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunobiology of respiratory syncytial virus: prospects for a vaccine.
    Norrby E; Akerlind B; Mufson MA
    Adv Exp Med Biol; 1989; 257():147-53. PubMed ID: 2694814
    [No Abstract]   [Full Text] [Related]  

  • 13. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein.
    Brideau RJ; Walters RR; Stier MA; Wathen MW
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2637-44. PubMed ID: 2677234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress toward the development of a respiratory syncytial virus vaccine.
    Ewasyshyn M; Klein M
    Pediatr Pulmonol Suppl; 1995; 11():81-3. PubMed ID: 7547360
    [No Abstract]   [Full Text] [Related]  

  • 15. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.
    Piazza FM; Johnson SA; Darnell ME; Porter DD; Hemming VG; Prince GA
    J Virol; 1993 Mar; 67(3):1503-10. PubMed ID: 8437227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The immunization of adults against respiratory syncytial virus infection].
    Leshchinskaia NP; Korchanova NL; Pokrovskaia EE; Efremov BV; Padalko IuV
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Oct; (10):49-53. PubMed ID: 2609811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular biology of paramyxoviruses and its significance for the development of vaccines].
    Scheid A
    Internist (Berl); 1985 Feb; 26(2):98-102. PubMed ID: 3884533
    [No Abstract]   [Full Text] [Related]  

  • 20. T-cells in respiratory syncytial virus (RSV) infection.
    Askonas BA; Openshaw P; Cannon M
    Adv Exp Med Biol; 1989; 257():9-17. PubMed ID: 2533461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.